Actinium Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 14.08

ATNM Stock  USD 1.30  0.02  1.52%   
Actinium Pharmaceuticals' future price is the expected price of Actinium Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Actinium Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Actinium Pharmaceuticals Backtesting, Actinium Pharmaceuticals Valuation, Actinium Pharmaceuticals Correlation, Actinium Pharmaceuticals Hype Analysis, Actinium Pharmaceuticals Volatility, Actinium Pharmaceuticals History as well as Actinium Pharmaceuticals Performance.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.
  
At this time, Actinium Pharmaceuticals' Price To Sales Ratio is very stable compared to the past year. As of the 11th of December 2024, Price Book Value Ratio is likely to grow to 3.90, while Price Earnings To Growth Ratio is likely to drop (0.08). Please specify Actinium Pharmaceuticals' target price for which you would like Actinium Pharmaceuticals odds to be computed.

Actinium Pharmaceuticals Target Price Odds to finish over 14.08

The tendency of Actinium Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 14.08  or more in 90 days
 1.30 90 days 14.08 
close to zero percent
Based on a normal probability distribution, the odds of Actinium Pharmaceuticals to move over $ 14.08  or more in 90 days from now is close to zero percent (This Actinium Pharmaceuticals probability density function shows the probability of Actinium Stock to fall within a particular range of prices over 90 days) . Probability of Actinium Pharmaceuticals price to stay between its current price of $ 1.30  and $ 14.08  at the end of the 90-day period is about 97.0 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.71 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Actinium Pharmaceuticals will likely underperform. Additionally Actinium Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Actinium Pharmaceuticals Price Density   
       Price  

Predictive Modules for Actinium Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Actinium Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.071.335.88
Details
Intrinsic
Valuation
LowRealHigh
1.177.8712.42
Details
Naive
Forecast
LowNextHigh
0.031.445.98
Details
6 Analysts
Consensus
LowTargetHigh
25.1227.6030.64
Details

Actinium Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Actinium Pharmaceuticals is not an exception. The market had few large corrections towards the Actinium Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Actinium Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Actinium Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.62
β
Beta against Dow Jones1.71
σ
Overall volatility
0.20
Ir
Information ratio -0.12

Actinium Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Actinium Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Actinium Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Actinium Pharmaceuticals generated a negative expected return over the last 90 days
Actinium Pharmaceuticals may become a speculative penny stock
Actinium Pharmaceuticals has high historical volatility and very poor performance
The company reported the previous year's revenue of 81 K. Net Loss for the year was (48.82 M) with profit before overhead, payroll, taxes, and interest of 1.03 M.
Actinium Pharmaceuticals currently holds about 116.33 M in cash with (47.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from businesswire.com: NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225

Actinium Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Actinium Stock often depends not only on the future outlook of the current and potential Actinium Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Actinium Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding26.6 M
Cash And Short Term Investments76.7 M

Actinium Pharmaceuticals Technical Analysis

Actinium Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Actinium Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Actinium Pharmaceuticals. In general, you should focus on analyzing Actinium Stock price patterns and their correlations with different microeconomic environments and drivers.

Actinium Pharmaceuticals Predictive Forecast Models

Actinium Pharmaceuticals' time-series forecasting models is one of many Actinium Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Actinium Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Actinium Pharmaceuticals

Checking the ongoing alerts about Actinium Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Actinium Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Actinium Pharmaceuticals generated a negative expected return over the last 90 days
Actinium Pharmaceuticals may become a speculative penny stock
Actinium Pharmaceuticals has high historical volatility and very poor performance
The company reported the previous year's revenue of 81 K. Net Loss for the year was (48.82 M) with profit before overhead, payroll, taxes, and interest of 1.03 M.
Actinium Pharmaceuticals currently holds about 116.33 M in cash with (47.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from businesswire.com: NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225
When determining whether Actinium Pharmaceuticals is a strong investment it is important to analyze Actinium Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Actinium Pharmaceuticals' future performance. For an informed investment choice regarding Actinium Stock, refer to the following important reports:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.39)
Revenue Per Share
0.003
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.31)
Return On Equity
(0.88)
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.